Developer docs
API playgroundTry for free, no card

Search company profiles

FDNA

Full company profile

uuid003hkav

Namestring
FDNA
Legal namestring
FDNA Inc.
Websiteurl
fdna.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

FDNA is a Boston-headquartered, Delaware-incorporated healthcare AI company (also listed with operational headquarters in Atlanta, GA) that develops facial dysmorphology and multi-modal phenotype analysis technology for detecting developmental delays, genetic disorders, and rare diseases. Its core product, Face2Gene, is an AI-powered phenotypic analysis tool used by geneticists, pediatric specialists, and other clinicians; the consumer-facing Family Health Checker app extends the same technology to parents for self-assessment and specialist routing. Underlying the products is a proprietary multi-modal algorithm framework that integrates image analysis, natural language processing, video analysis, voice analysis, and structured symptom data through 10+ named algorithms including Deep Gestalt®, Gestalt Matcher™, D-Score™, A-Score™, Feature Match™, Feature Extraction, Heat Maps, Focus Assessment, Clinical Notes Analyzer, and Symptom Assessment, all mapping outputs to Human Phenotype Ontology (HPO) terms.

The company generates revenue through four documented streams: subscription access to Face2Gene for healthcare professionals, targeted advertising by pharmaceutical companies on the Family Health Checker app, subscription-based data and patient-recruitment services sold to Contract Research Organizations, and AI-driven patient engagement and decision support tools sold to health services. Pricing for healthcare professionals, pharma, CROs, and health systems is not publicly disclosed and follows an enterprise inquiry-led sales motion; the consumer app is free. FDNA serves a diversified customer set spanning parents/patients, pediatric and genetic specialists, pharma, CROs, researchers, and health services, with the platform deployed across 10,000+ medical centers in 130+ countries and supported by 100+ peer-reviewed publications. FDNA is privately held with 11–50 employees, no disclosed funding rounds, no parent company, and a Scientific Advisory Board chaired by Michael Hayden with Karen Gripp as Chief Medical Officer.

Short descriptiontext

FDNA is an AI-native healthcare technology company that builds multi-modal phenotype analysis algorithms (Deep Gestalt, Gestalt Matcher) for early detection of developmental and genetic disorders, serving clinicians via Face2Gene, parents via a free Family Health Checker app, and pharma and CROs through data and patient-recruitment services across 10,000+ medical centers in 130+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSunrise, United States
HQ citystring
Sunrise
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
facial dysmorphology analysis, AI phenotyping software, genetic disorder diagnosis, rare disease detection, clinical decision support
Industry1 code
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Genetics AI Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Healthcare Professional Tools (Face2Gene)
TypeSubscription Recurring
Description

Face2Gene provides advanced AI-powered phenotypic analysis for genetic specialists. Healthcare professionals pay for access to decision support tools and comprehensive genetic databases. The platform enhances patient engagement and streamlines the diagnostic process.

fdna.com
2Pharma Company Advertising
TypeAdvertising
Description

FDNA enables pharmaceutical companies to promote their medications on the Family Health Checker app platform based on patient symptoms and AI analysis, ensuring targeted advertising to relevant audiences.

fdna.com
3CRO Data Access & Recruitment
TypeSubscription Recurring
Description

FDNA provides CROs with access to a vast network of patients, healthcare providers, and a comprehensive data clearing house. AI-based analysis tools enhance patient recruitment for clinical trials.

fdna.com
4Health Services Patient Engagement
TypeSubscription Recurring
Description

Health services pay for AI-based patient engagement solutions, decision support tools, and care management tools. The platform helps them connect with broader patient audiences and improve diagnostic capabilities.

fdna.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Free Family Health Checker for Parents
ModelFreemiumBilling cadenceMonthly
Notes

The Family Health Checker app is free for parents to use for initial assessment and AI-powered analysis. This enables broad consumer access while driving engagement with healthcare providers.

fdna.com
2Professional Healthcare Tools (Face2Gene)
ModelSubscriptionBilling cadenceAnnual
Notes

Face2Gene provides advanced genetic analysis tools for healthcare professionals. Pricing not publicly disclosed - requires inquiry and custom onboarding process.

fdna.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1Face2Gene
Description

AI-powered phenotypic analysis tool for genetic specialists to expedite diagnosis of rare diseases

fdna.com
+6 more records
Core offering1 text field

FDNA develops AI-powered facial analysis and multi-modal phenotyping software that helps healthcare professionals detect and diagnose developmental, genetic, and rare disorders. Its flagship Face2Gene platform uses proprietary algorithms (Deep Gestalt, Gestalt Matcher, D-Score, A-Score, etc.) to map patient images and clinical features to potential syndromes, while the free Family Health Checker app lets parents run AI-based developmental assessments. The company also operates a data clearing house and provides vertical-specific services for pharmaceutical companies, contract research organizations (CROs), and researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Used in 10,000+ medical centers worldwide
+3 more records
Product overview1 text field

FDNA is an AI-powered healthcare technology company offering a multi-product portfolio centered on early detection and diagnosis of developmental and genetic disorders. The core offerings include Face2Gene (AI phenotypic analysis for healthcare professionals), the Family Health Checker App (AI-powered assessment tool for parents), and the FDNA Healthcare Professional Tools (decision support and patient engagement suite). These products integrate across multiple modalities including facial image analysis, symptom assessment, NLP, video analysis, and voice analysis. The platform is used in over 10,000 medical centers across 130+ countries and is backed by a multi-modal AI framework comprising algorithms including Deep Gestalt, Gestalt Matcher, Feature Extraction, Heat Maps, Focus Assessment, Feature Match, Clinical Notes Analyzer, Symptom Assessment, D-Score, and A-Score. The platform serves diverse stakeholders including parents, healthcare providers (pediatric specialists, geneticists, health services), pharmaceutical companies, CROs, and researchers.

Product and service6 records
1Face2Gene
CategoryClinical decision support software
Description

AI-powered phenotypic analysis platform used by licensed healthcare professionals (geneticists, pediatric specialists) to analyze facial images and patient features, surface potential genetic syndromes, and support diagnostic workflows for developmental and rare diseases. Outputs are non-diagnostic and intended for clinical decision support.

2Family Health Checker App
CategoryConsumer health assessment app
Description

Free AI-powered mobile and web app for parents and patients to assess a child's developmental concerns, run symptom and image-based assessments, and receive reports to share with healthcare providers. Currently available only in the US and serves as a digital front door for FDNA's healthcare provider and pharma partners.

3FDNA Data Clearing House
CategoryHealthcare data and interoperability platform
Description

Interoperability and data platform offering streamlined connectivity between healthcare providers, patients, pharma companies, therapy services, and contract research organizations, leveraging FDNA's phenotypic database for matching, recruitment, and research use cases.

4FDNA for Pharma Companies
CategoryPharma commercial and drug discovery services
Description

Service offering for pharmaceutical companies that combines targeted drug promotion on the Family Health Checker app (based on patient symptoms and AI analysis) with access to FDNA's patient and provider network, AI-driven drug discovery inputs, and clinical trial support.

5FDNA for CROs
CategoryClinical research services
Description

Service for contract research organizations providing AI-based patient recruitment, access to FDNA's diverse phenotypic patient and provider network, and analytical tools to expand clinical trial portfolios, especially for rare and genetic disease studies.

6FDNA for Researchers
CategoryResearch data and analytics services
Description

Service for academic and translational researchers providing AI-driven analysis tools, access to FDNA's comprehensive genetic and phenotypic database, precise phenotyping, and deep learning algorithms to support genetic and rare disease research projects.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical genetic testing company spanning reproductive health, oncology, and rare disease with substantial hospital channel presence. Comparable on clinical genomics customer overlap, though Natera is a much larger testing-services incumbent rather than a phenotype-AI specialist.

TypeBroad incumbent
Description

Medical imaging AI subsidiary of RadNet, applying computer vision and deep learning across radiology workflows. Comparable on the medical imaging AI technology stack, but focused on radiology rather than pediatric phenotypic analysis, and operates within a much larger imaging services platform.

TypeBroad incumbent
Description

Large clinical genetic testing laboratory serving hospitals, clinicians, and patients across hereditary disease areas. Overlapping clinical geneticist customer base and rare disease use cases, but operates a lab-based testing model rather than AI phenotypic decision support, making FDNA a complementary or upstream tool.

TypeBroad incumbent
Description

Molecular diagnostics company (Roche subsidiary) providing genomic profiling for oncology with biopharma data partnerships. Comparable on the biopharma data clearing house and clinical genomics customer overlap, though focused on oncology rather than rare genetic disease and operated at substantially greater scale.

5Tempus Labs
TypeBroad incumbent
Description

AI-driven precision medicine company combining multi-modal data (clinical, molecular, imaging) for oncology and broader disease areas. Comparable on multi-modal AI infrastructure and pharma/CRO data partnerships, but Tempus is a much broader, well-capitalized player focused primarily on oncology rather than pediatric rare disease.

TypeEmerging player
Description

Pediatric genomics program delivering rapid whole genome sequencing for critically ill newborns with suspected genetic disease. Overlapping rare pediatric genetic disease mission and clinical user base, though structured as a research-driven institute rather than a commercial SaaS platform.

TypeEmerging player
Description

AI-driven genomics company applying machine learning to large-scale genetic and phenotypic data for drug discovery and clinical insight. Comparable on AI-over-phenotype-and-genomics positioning and biopharma customer overlap, but with research and pharma focus rather than point-of-care clinician decision support.

TypeDirect peer
Description

AI-driven clinical genomics analysis platform serving hospitals and clinical geneticists worldwide with a SaaS subscription model. Closest direct peer—same customer base (clinical geneticists, hospital labs), same AI-decision-support category, and similar revenue motion around rare disease and hereditary oncology workflows.

TypeDirect peer
Description

Whole genome and exome sequencing diagnostics company focused on rare disease and neurological disorder diagnosis. Comparable on rare disease clinical customer base, though Variantyx operates as a sequencing lab whereas FDNA provides AI decision support upstream and alongside testing.

TypeDirect peer
Description

AI-based genomic interpretation platform purpose-built for rare disease variant prioritization, used by clinical labs and pediatric hospitals. Directly comparable on the rare disease AI decision-support category, although focused on sequence variant analysis rather than FDNA's phenotypic image analysis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FDNA

Clinical Genetics AI Softwarefdna.com

FDNA is an AI-native healthcare technology company that builds multi-modal phenotype analysis algorithms (Deep Gestalt, Gestalt Matcher) for early detection of developmental and genetic disorders, serving clinicians via Face2Gene, parents via a free Family Health Checker app, and pharma and CROs through data and patient-recruitment services across 10,000+ medical centers in 130+ countries.

What FDNA does

FDNA is a Boston-headquartered, Delaware-incorporated healthcare AI company (also listed with operational headquarters in Atlanta, GA) that develops facial dysmorphology and multi-modal phenotype analysis technology for detecting developmental delays, genetic disorders, and rare diseases. Its core product, Face2Gene, is an AI-powered phenotypic analysis tool used by geneticists, pediatric specialists, and other clinicians; the consumer-facing Family Health Checker app extends the same technology to parents for self-assessment and specialist routing. Underlying the products is a proprietary multi-modal algorithm framework that integrates image analysis, natural language processing, video analysis, voice analysis, and structured symptom data through 10+ named algorithms including Deep Gestalt®, Gestalt Matcher™, D-Score™, A-Score™, Feature Match™, Feature Extraction, Heat Maps, Focus Assessment, Clinical Notes Analyzer, and Symptom Assessment, all mapping outputs to Human Phenotype Ontology (HPO) terms.

The company generates revenue through four documented streams: subscription access to Face2Gene for healthcare professionals, targeted advertising by pharmaceutical companies on the Family Health Checker app, subscription-based data and patient-recruitment services sold to Contract Research Organizations, and AI-driven patient engagement and decision support tools sold to health services. Pricing for healthcare professionals, pharma, CROs, and health systems is not publicly disclosed and follows an enterprise inquiry-led sales motion; the consumer app is free. FDNA serves a diversified customer set spanning parents/patients, pediatric and genetic specialists, pharma, CROs, researchers, and health services, with the platform deployed across 10,000+ medical centers in 130+ countries and supported by 100+ peer-reviewed publications. FDNA is privately held with 11–50 employees, no disclosed funding rounds, no parent company, and a Scientific Advisory Board chaired by Michael Hayden with Karen Gripp as Chief Medical Officer.

FDNA firmographics

Firmographics
Name
FDNA
Legal name
FDNA Inc.
Website
https://fdna.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
FDNA is an AI-native healthcare technology company that builds multi-modal phenotype analysis algorithms (Deep Gestalt, Gestalt Matcher) for early detection of developmental and genetic disorders, serving clinicians via Face2Gene, parents via a free Family Health Checker app, and pharma and CROs through data and patient-recruitment services across 10,000+ medical centers in 130+ countries.
Ownership category
akta.pro rank

Where FDNA is headquartered

Location

Headquarters

HQ city
Sunrise
HQ country
United States
HQ region
North America

Offices2 records

Markets served

FDNA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Healthcare Professional Tools (Face2Gene): Face2Gene provides advanced AI-powered phenotypic analysis for genetic specialists. Healthcare professionals pay for access to decision support tools and comprehensive genetic databases. The platform enhances patient engagement and streamlines the diagnostic process.
  2. Pharma Company Advertising: FDNA enables pharmaceutical companies to promote their medications on the Family Health Checker app platform based on patient symptoms and AI analysis, ensuring targeted advertising to relevant audiences.
  3. CRO Data Access & Recruitment: FDNA provides CROs with access to a vast network of patients, healthcare providers, and a comprehensive data clearing house. AI-based analysis tools enhance patient recruitment for clinical trials.
  4. Health Services Patient Engagement: Health services pay for AI-based patient engagement solutions, decision support tools, and care management tools. The platform helps them connect with broader patient audiences and improve diagnostic capabilities.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree Family Health Checker for Parents
SubscriptionAnnualProfessional Healthcare Tools (Face2Gene)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

FDNA product offering

Product offering

Core offering

FDNA develops AI-powered facial analysis and multi-modal phenotyping software that helps healthcare professionals detect and diagnose developmental, genetic, and rare disorders. Its flagship Face2Gene platform uses proprietary algorithms (Deep Gestalt, Gestalt Matcher, D-Score, A-Score, etc.) to map patient images and clinical features to potential syndromes, while the free Family Health Checker app lets parents run AI-based developmental assessments. The company also operates a data clearing house and provides vertical-specific services for pharmaceutical companies, contract research organizations (CROs), and researchers.

Product overview

FDNA is an AI-powered healthcare technology company offering a multi-product portfolio centered on early detection and diagnosis of developmental and genetic disorders. The core offerings include Face2Gene (AI phenotypic analysis for healthcare professionals), the Family Health Checker App (AI-powered assessment tool for parents), and the FDNA Healthcare Professional Tools (decision support and patient engagement suite). These products integrate across multiple modalities including facial image analysis, symptom assessment, NLP, video analysis, and voice analysis. The platform is used in over 10,000 medical centers across 130+ countries and is backed by a multi-modal AI framework comprising algorithms including Deep Gestalt, Gestalt Matcher, Feature Extraction, Heat Maps, Focus Assessment, Feature Match, Clinical Notes Analyzer, Symptom Assessment, D-Score, and A-Score. The platform serves diverse stakeholders including parents, healthcare providers (pediatric specialists, geneticists, health services), pharmaceutical companies, CROs, and researchers.

Differentiator

Problem solved

Functional benefit

Brands

  • Face2Gene: AI-powered phenotypic analysis tool for genetic specialists to expedite diagnosis of rare diseases
  • Family Health Checker
  • Deep Gestalt®
  • Gestalt Matcher™
  • D-Score™
  • A-Score™
  • Feature Match™

Products and services

  • Face2Gene AI-powered phenotypic analysis platform used by licensed healthcare professionals (geneticists, pediatric specialists) to analyze facial images and patient features, surface potential genetic syndromes, and support diagnostic workflows for developmental and rare diseases. Outputs are non-diagnostic and intended for clinical decision support.
  • Family Health Checker App Free AI-powered mobile and web app for parents and patients to assess a child's developmental concerns, run symptom and image-based assessments, and receive reports to share with healthcare providers. Currently available only in the US and serves as a digital front door for FDNA's healthcare provider and pharma partners.
  • FDNA Data Clearing House Interoperability and data platform offering streamlined connectivity between healthcare providers, patients, pharma companies, therapy services, and contract research organizations, leveraging FDNA's phenotypic database for matching, recruitment, and research use cases.
  • FDNA for Pharma Companies Service offering for pharmaceutical companies that combines targeted drug promotion on the Family Health Checker app (based on patient symptoms and AI analysis) with access to FDNA's patient and provider network, AI-driven drug discovery inputs, and clinical trial support.
  • FDNA for CROs Service for contract research organizations providing AI-based patient recruitment, access to FDNA's diverse phenotypic patient and provider network, and analytical tools to expand clinical trial portfolios, especially for rare and genetic disease studies.
  • FDNA for Researchers Service for academic and translational researchers providing AI-driven analysis tools, access to FDNA's comprehensive genetic and phenotypic database, precise phenotyping, and deep learning algorithms to support genetic and rare disease research projects.

Quantifiable outcome

  • Used in 10,000+ medical centers worldwide
  • +3 more outcomes

Companies that use FDNA

Customer profile

Segments7 records

Ideal customer profiles6 records

FDNA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature10 records

FDNA partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

FDNA competitors and assessment

Company assessment

Broad incumbents

  • Natera: Clinical genetic testing company spanning reproductive health, oncology, and rare disease with substantial hospital channel presence. Comparable on clinical genomics customer overlap, though Natera is a much larger testing-services incumbent rather than a phenotype-AI specialist.
  • DeepHealth (RadNet): Medical imaging AI subsidiary of RadNet, applying computer vision and deep learning across radiology workflows. Comparable on the medical imaging AI technology stack, but focused on radiology rather than pediatric phenotypic analysis, and operates within a much larger imaging services platform.
  • Invitae: Large clinical genetic testing laboratory serving hospitals, clinicians, and patients across hereditary disease areas. Overlapping clinical geneticist customer base and rare disease use cases, but operates a lab-based testing model rather than AI phenotypic decision support, making FDNA a complementary or upstream tool.
  • Foundation Medicine: Molecular diagnostics company (Roche subsidiary) providing genomic profiling for oncology with biopharma data partnerships. Comparable on the biopharma data clearing house and clinical genomics customer overlap, though focused on oncology rather than rare genetic disease and operated at substantially greater scale.
  • Tempus Labs: AI-driven precision medicine company combining multi-modal data (clinical, molecular, imaging) for oncology and broader disease areas. Comparable on multi-modal AI infrastructure and pharma/CRO data partnerships, but Tempus is a much broader, well-capitalized player focused primarily on oncology rather than pediatric rare disease.

Emerging players

  • Rady Children's Institute for Genomic Medicine: Pediatric genomics program delivering rapid whole genome sequencing for critically ill newborns with suspected genetic disease. Overlapping rare pediatric genetic disease mission and clinical user base, though structured as a research-driven institute rather than a commercial SaaS platform.
  • Genomics plc: AI-driven genomics company applying machine learning to large-scale genetic and phenotypic data for drug discovery and clinical insight. Comparable on AI-over-phenotype-and-genomics positioning and biopharma customer overlap, but with research and pharma focus rather than point-of-care clinician decision support.

Direct peers

  • SOPHiA GENETICS: AI-driven clinical genomics analysis platform serving hospitals and clinical geneticists worldwide with a SaaS subscription model. Closest direct peer—same customer base (clinical geneticists, hospital labs), same AI-decision-support category, and similar revenue motion around rare disease and hereditary oncology workflows.
  • Variantyx: Whole genome and exome sequencing diagnostics company focused on rare disease and neurological disorder diagnosis. Comparable on rare disease clinical customer base, though Variantyx operates as a sequencing lab whereas FDNA provides AI decision support upstream and alongside testing.
  • Fabric Genomics: AI-based genomic interpretation platform purpose-built for rare disease variant prioritization, used by clinical labs and pediatric hospitals. Directly comparable on the rare disease AI decision-support category, although focused on sequence variant analysis rather than FDNA's phenotypic image analysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

FDNA social profiles

Digital presence

FDNA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FDNA leadership team

Management profile

Number of profiles

Profiles3 records

FDNA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FDNA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FDNA

What does FDNA do?

FDNA develops AI-powered facial analysis and multi-modal phenotyping software that helps healthcare professionals detect and diagnose developmental, genetic, and rare disorders. Its flagship Face2Gene platform uses proprietary algorithms (Deep Gestalt, Gestalt Matcher, D-Score, A-Score, etc.) to map patient images and clinical features to potential syndromes, while the free Family Health Checker app lets parents run AI-based developmental assessments. The company also operates a data clearing house and provides vertical-specific services for pharmaceutical companies, contract research organizations (CROs), and researchers.

Is FDNA a public or private company?

FDNA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was FDNA founded?

FDNA was founded in 2011. It employs 11 to 50 people.

Where is FDNA based?

FDNA is headquartered in Sunrise, United States, in the North America region.

How does FDNA make money?

Four revenue lines are on record. Healthcare Professional Tools (Face2Gene) is the primary driver. The others are pharma Company Advertising, CRO Data Access & Recruitment and health Services Patient Engagement.

Who are FDNA's main competitors?

Broad incumbents on record are Natera, DeepHealth (RadNet), Invitae, Foundation Medicine and Tempus Labs. Emerging players are Rady Children's Institute for Genomic Medicine and Genomics plc. Direct peers are SOPHiA GENETICS, Variantyx and Fabric Genomics.

Does FDNA have an API?

No public API is recorded for FDNA.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GoogleFace2Gene, Smartphone App Uses Facial Recognition AI to Diagnose Genetic DisordersFDNA's Face2Gene app uses facial recognition AI to detect rare genetic disorders, published in Nature Medicine. It correctly identified top diagnoses in about 65% of cases and top ten in 90% of cases. FDNA plans to expand the technology for genetic variant analysis.The HinduFDNA accuses A.P. government of land grabs in North Andhra without any real developmentThe Forum for Development of North Andhra (FDNA) organized a round table meeting on Thursday where allegations were made that lands and natural resources in the region are being handed over to corporate groups under the guise of development. K.S. Chalam, a former UPSC member, specifically alleged large-scale land acquisition in North Andhra, including 13.74 acres of prime land near RK Beach in Visakhapatnam being allotted to LuLu Mall, claiming this violates various laws.PR NewswireFDNA Publishes Study in Nature Genetics Describing Breakthrough in AI for Rare Disease IdentificationFDNA announced that its breakthrough study on AI-powered facial analysis technology for rare disease identification was published in Nature Genetics, demonstrating that GestaltMatcher can identify facial representations of over 1,000 rare genetic diseases and match one-third of cases with ultra-rare or novel disorders. The study analyzed 17,560 portrait photos from patients with 1,115 rare disorders and found the technology can accelerate clinical diagnosis of patients with undiagnosed conditions. FDNA reports that its technology is used by 70% of the world's clinicians and researchers in human genetics across 2,000 clinical sites from over 130 countries.SuperbCrewAn Interview With Ido Rabiner, Chief Operating Officer At FDNA TelehealthFDNA Telehealth, founded in 2011, provides online genetic counseling and facial image analysis for rare disease patients. The company aims to shorten diagnostic odysseys and is working on insurance reimbursement, expanding languages, and adding more counselors and labs.PrwebFDNA Telehealth AI Telegenetics Platform: Immediate Access to Genetic Analysis for Rare DiseasesFDNA Telehealth launched a telegenetics platform using AI facial screening to provide genetic analysis for rare diseases from home. The platform connects patients to genetic specialists and is used by over 10,000 hospitals, with in-network insurance coverage planned. It aims to shorten the average five-year diagnostic journey for rare genetic syndromes.GoogleAI Tech Uses Facial Analysis To Detect Genetic DisordersFDNA's DeepGestalt AI uses facial analysis to help diagnose genetic disorders, trained on 150,000 patients and correctly labeling over 200 syndromes. In a test, it identified disorders in 502 photos 91% of the time. The company plans to expand the technology using clinical notes, images, and video.NoCamelsAI Tech Uses Facial Analysis To Detect Rare Genetic DisordersFDNA's DeepGestalt AI uses facial analysis to help diagnose rare genetic disorders, trained on over 150,000 patients. It correctly identified 200+ syndromes and achieved 91% accuracy in tests. The company plans to expand the technology using clinical notes, images, and video.GoogleFace-Scanning AI Identifies Rare Genetic DisordersFDNA's DeepGestalt AI system identifies rare genetic disorders from facial images, outperforming clinicians in three experiments. In a study of 17,000 children, it correctly distinguished Noonan syndrome subtypes 64% of the time versus 20% for clinicians. The company warns of potential misuse and suggests blockchain monitoring.Ars TechnicaAI can diagnose some genetic disorders using photos of facesFDNA's DeepGestalt AI diagnoses genetic disorders from facial images, outperforming clinicians. Tested on Cornelia de Lange and Angelman syndromes, it achieved over 90% accuracy versus 70-75% for experts. The system was trained on 500,000 images from 10,000 subjects.GoogleAI Uses Face Scans to Diagnose Rare Genetic DisordersFDNA developed Face2Gene, a deep-learning app that identifies rare genetic disorders from facial photos. It achieves 91% top-10 accuracy across 215 syndromes and outperformed clinical experts in three experiments. The app is free for doctors, with a database of about 150,000 images.